Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 21, 2020 - Issue 1-2
Submit an article Journal homepage
599
Views
7
CrossRef citations to date
0
Altmetric
Clinical

The revised El Escorial criteria “clinically probable laboratory supported ALS”—once a promising now a superfluous category?

Nathalie Braun1 Neuromuscular Diseases Unit/ALS Clinic, Cantonal Hospital St. Gallen, St. Gallen, Switzerland, Correspondence[email protected]
,
Eric A. Macklin2 Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA, ;3 Harvard Medical School, Boston, MA, USA, and
,
Ervin Sinani4 Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA, USA
,
Alexander Sherman3 Harvard Medical School, Boston, MA, USA, and ;4 Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA, USA
,
Markus Weber1 Neuromuscular Diseases Unit/ALS Clinic, Cantonal Hospital St. Gallen, St. Gallen, Switzerland,
& the Pooled Resource Open-Access ALS Clinical Trials Consortium
Pages 24-28 | Received 21 May 2019, Accepted 08 Sep 2019, Published online: 27 Sep 2019

References

  • Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
  • Agosta F, Al-Chalabi A, Filippi M, Hardiman O, Kaji R, Meininger V, et al. The El Escorial criteria: strengths and weaknesses. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:1–7.
  • Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059–67.
  • Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, et al. A revision of the El Escorial criteria – 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:291–2.
  • Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
  • Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–7.
  • Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83:1719–25.
  • Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2005;77:390–2.
  • Belsh JM. ALS diagnostic criteria of El Escorial revisited: do they meet the need of clinicians as well as researchers? ALS Other Motor Neuron Disord. 2000;1:S57–S60.
  • Ross MA, Miller RG, Berchert L, Parry G, Barohn RJ, Armon C, et al. Toward earlier diagnosis of amyotrophic lateral sclerosis. Revised criteria. Neurology. 1998;50:768–72.
  • de Carvalho M. Testing upper motor neuron function in amyotrophic lateral sclerosis: the most difficult task of neurophysiology. Brain. 2012;135:2581–2.
  • Swash M. Why are upper motor neuron signs difficult to elicit in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2012;83:659–62.
  • de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurol. 2008;119:497–503.
  • Johnsen B, Pugdahl K, Fuglsang-Frederiksen A, Kollewe K, Paracka L, Dengler R, et al. Diagnostic criteria for amyotrophic lateral sclerosis: a multicentre study of inter-rater variation and sensitivity. Clin Neurophysiol. 2019;130:307–14.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.